- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07933380
A Case Study to Assess a Brightening Skincare Regimen in Patients With Bothersome Skin Dark Spots
A Single-Center, Open-Label Case Study to Assess a Brightening Skincare Regimen in Patients With Bothersome Skin Dark Spots
This 12- week, single-center, open-label case study is being conducted to assess the efficacy and tolerance of a brightening skincare regimen comprised of a facial wash, brightening serum, brightening exfoliating pads, face cream and sunscreen by healthy females with clinically determined mild to moderate Post-inflammatory hyperpigmentation (PIH).
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
At Visit 1, prior to the start of the study, prospective subjects will be screened for eligibility requirements based on inclusion and exclusion criteria and will be enrolled into the study. Prospective subjects will be given an Institutional Review Board (IRB)-approved Informed Consent Form (ICF) and photography release form (PRF) to read and sign. Subjects will be provided the pre-washout skincare products, written usage instructions, and a daily diary.
At Baseline (Visit 2), subjects will have their face evaluated by a board-certified dermatology for clinical efficacy parameters (skin tone evenness, overall appearance, and PIH) and evaluate tolerability (Erythema, edema, and dryness) parameters. Subjects will then rate the Itching, Burning, and Stinging and complete a self-assessment questionnaire (SAQ). A clinical staff will take standardized clinical photographs using VISIA® Imaging.
At Visit 3, 4, 5, and 6 dermatologist clinical efficacy and tolerability, as well as subject tolerability assessments will be performed, followed by clinical photography. Subjects will complete an SAQ before the visit ends.
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
Texas
-
The Woodlands, Texas, Forente stater, 77380
- REVE Dermatology and Aesthetics
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Female (biological), 25 to 55 years of age
- Having Fitzpatrick skin type I-VI (refer to Appendix I: Fitzpatrick Skin Type)
- Having mild to moderate Post-Inflammatory Hyperpigmentation as identified as a grade 2 or 3 on the 5-point Investigator Global Assessment Scale [ 0 = clear, 1 = Almost Clear, 2 = Mild, 3 = Moderate, 4 = Severe]
- Having active Post-Inflammatory Hyperpigmentation due to blemish-prone skin with no active breakouts within the last 3 months
- Having active PIH due to sun exposure, rosacea, and procedures
- Self-perceived very bothersome hyperpigmentation (darkening), including spots, on the global face
- In good general health (physical, mental, and social well-being, not merely the absence of disease/infirmity), according to subject self-report.
Exclusion Criteria:
- Breastfeeding, pregnancy, or planning to become pregnant
- Having been diagnosed with known allergies to skin care products
- Having a known reactivity to tranexamic acid, niacinamide, sunflower seed, coconut, rosemary, barley, goji, sandalwood, licorice root, radish root, beeswax, yeast, ascorbic acid, tetrahexyldecyl ascorbate, and/or any of the ingredients in the study products
- Having a health condition and/or pre-existing or dormant dermatologic disease on the face
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Brightening Serum and Brightening Pads
From baseline to week 12, subjects will apply a Brightening Serum (2x daily), and brightening pads 3 times per week in the evening only (Monday, Wednesday, Friday) or (Tuesday, Thursday, Saturday). |
From baseline to week 12, subjects will use a Brightening Facial Wash (2x daily), Facial Moisturizer (2x daily), and broad-spectrum sunscreen moisturizer SPF 50 (morning only). Participants were asked to apply the sunscreen if sun exposure was more than 30 minutes per day. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Improvement of Clinical Efficacy Parameters at 2, 4, 8, and 12 weeks versus Baseline
Tidsramme: Weeks 2, 4, 8, and 12 compared to baseline
|
A board-certified dermatologist will grade skin tone evenness, overall appearance, and PIH at baseline and at weeks 2, 4, 8, and 12. Skin tone evenness and overall appearance will be graded using the modified Griffiths 10-point scale (0 = Even healthy skin color; 9 = Uneven, discolored appearance), while PIH will be measured using a 4-point investigator global assessment scale (0 = clear, 1 = mild, 2 = moderate, and 3 = severe). Higher scores indicate greater severity of the respective skin condition, where a decrease in score indicates an improvement. |
Weeks 2, 4, 8, and 12 compared to baseline
|
|
Measurement of subject self assessment questionnaire
Tidsramme: Baseline, weeks 2, 4, 8, and 12
|
Subjects will complete a self-assessment questionnaire which will consist of a series of questions related to subjects' evaluation of product efficacy and attributes. Subjects are asked to rate based on a scoring system of the following: from 5 (completely agree) to 1 (completely disagree). The best outcome is to Completely Agree with the statement / question being asked. |
Baseline, weeks 2, 4, 8, and 12
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Lack of Significant Increase in Objective Tolerability Parameters at weeks, 2, 4, 8, 12 compared to Baseline
Tidsramme: Baseline, weeks 2, 4, 8, and 12
|
Clinical grading of Objective Irritation Parameters (Erythema, Edema, and Dryness) evaluated by investigator and subject reporting of Subjective Irritation Parameters (Burning, Stinging, Itching) using a 4 point scale: 0 = None to 3 = Severe. A change in scores or lack of significant change at week 2, 4, 8 and 12 compared to Baseline indicates tolerability/safety of the test material. A lower score indicating a better outcome. |
Baseline, weeks 2, 4, 8, and 12
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Hudsykdommer
- Pigmentasjonsforstyrrelser
- Hud- og bindevevssykdommer
- Hyperpigmentering
- Fysiologiske effekter av legemidler
- Dermatologiske midler
- Beskyttende agenter
- Strålebeskyttende midler
- Farmakologiske handlinger
- Kjemiske handlinger og bruk
- Terapeutisk bruk
- Spesialbruk av kjemikalier
- Kosmetikk
- Solkremer
Andre studie-ID-numre
- RS-2025-05
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .